Fischer Medical Ventures Ltd (FISCHER) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Fischer Medical Ventures Ltd on NSE and BSE, with an AI summary of each filing.
Appointment of Mr Chan Sing En as an Independent Director of FMV Global Innovations Pte.Ltd, Singapore, a Material Wholly Owned Subsidiary Company
Others (Uncategorized) · 27 Oct 2026, 8:23 pm
Fischer Medical Ventures Appoints Chan Sing En to Subsidiary Board Fischer Medical Ventures Limited has appointed Mr. Chan Sing En as an Independent Director on the Board of FMV Global Innovations Pte. Ltd., Singapore, an unlisted material wholly owned subsidiary, effective 27th Oct'26. Mr. Chan brings over three decades of experience in private equity, corporate finance, capital raising, and operational turnarounds across Southeast Asia and Australia. He currently serves as Principal and Director at SovCapital Pte Ltd and sits on the advisory board of FTAG Investment Bank, holding no relations to existing company directors.
Postal Ballot Notice & Scrutinizer
Others (Uncategorized) · 14 Oct 2026, 6:06 pm
Fischer Medical Ventures Board Approves Postal Ballot for Borrowing Limits and RPTs Fischer Medical Ventures' Board of Directors approved issuing a Postal Ballot Notice to seek shareholder approval for an increase in borrowing limits and certain material related party transactions at its meeting on 14th Oct'26. Additionally, the board approved the appointment of M/s Nuren Lodaya & Associates, Practicing Company Secretaries, as the scrutinizer to oversee the e-voting and remote e-voting process.
Scrutinizer Report and Voting Results for AGM 2026
Annual General Meeting · 01 Oct 2026, 10:17 pm
Proceedings of the 33rd AGM of the Company
Annual General Meeting · 29 Sept 2026, 11:10 pm
Intimation on Material transaction by the subsidiaries
Others (Uncategorized) · 29 Sept 2026, 12:00 am
Fischer Medical Ventures Subsidiaries Announce Substantial Dividend Declarations Fischer Medical Ventures Limited announced dividend declarations from three wholly owned material subsidiaries. On 28th Sep'26, Time Medical International Ventures (India) Private Limited and FlynnCare Health Innovations Private Limited declared dividends of Rs. 6.50 cr and Rs. 10.00 cr, respectively, for FY ended 31st Mar'26. Additionally, the board of FMV Global Innovation Pte Limited approved an interim dividend of USD 1.10 mn on 21st Sep'26 for the year ended 31st Mar'27, boosting cash inflows for the parent entity.
Corrigendum to the Annual Report for the FY 2025-26
Others (Uncategorized) · 26 Sept 2026, 11:47 pm
Fischer Medical Ventures Limited has informed the Exchange regarding Outcome of Board Meeting held on September 24, 2026.
Outcome · 25 Sept 2026, 4:50 pm
Fischer Medical Board Approves ₹50 Crore Total Investment in Wholly Owned Subsidiaries Fischer Medical Ventures' board approved investments totaling ₹50.00 Cr via rights issues across three material wholly owned subsidiaries on 24th Sep'26. The capital deployment comprises ₹11.50 Cr for 15,603 shares in Time Medical International Ventures (India) at ₹7,370.25 each, ₹12.50 Cr for 1,507 shares in Flynncare Health Innovations at ₹82,943.48 each, and ₹26.00 Cr for 53 shares in Singapore-based FMV Global Innovation Pte. Ltd. at ₹48,83,552.64 each. All transactions are done on an arm's-length cash basis, maintaining 100% ownership across the entities.
i) Rights Issue by Material Unlisted Subsidiary Companies ii) Investment in Equity shares of wholly owned Material Subsidiaries of the Company
Others (Uncategorized) · 24 Sept 2026, 11:33 pm
Fischer Medical Approves ₹50 Cr Capital Infusion Across Material Subsidiaries Fischer Medical Ventures' board approved investments totaling ₹50.00 Cr in rights issues of three wholly owned material subsidiaries on 24th Sep'26. The capital deployment includes ₹11.50 Cr for 15,603 shares in Time Medical International Ventures (India), ₹12.50 Cr for 1,507 shares in Flynncare Health Innovations, and ₹26.00 Cr for 53 shares in Singapore-based FMV Global Innovation Pte. Ltd. All transactions are all-cash subscriptions executed at arm's length based on registered valuer reports to support business growth across medical imaging, digital healthcare, and global diagnostics distribution.
Revised Presentation of Investor/Analyst call
Investor Presentation · 17 Sept 2026, 9:31 pm
Fischer Medical Ventures Outlines Integrated AI Healthcare Ecosystem Strategy Fischer Medical Ventures Limited submitted its revised investor presentation for the analyst call held on 7th Sep'26, detailing its platform combining AI-enabled medical imaging, population-scale screening, and hospital digitization. The ecosystem integrates Time Medical's proprietary imaging hardware (MRI, CT, X-Ray, mammography) and FlynnCare's diagnostic AI platforms (MIDAS, LIVE Dx, Clinics 2.0, ATLAS). Key portfolio offerings span helium-free and open MRI systems, portable AI X-rays, and portfolio companies NanoMedic, Obelab, Nervotec, and Nanyang Biologics. Geographies include India, the US, MENA, and SEA.
Chairman''s letter to shareholders
Others (Uncategorized) · 16 Sept 2026, 9:17 pm
Fischer Medical Ventures Outlines Multi-Segment Growth Strategy, Expansion, and Capital Infusion Fischer Medical Ventures operates across Radiology, Preventive Healthcare, and Wellness Solutions. In Radiology, key offerings include low-field and helium-free MRIs, CTs, and an order worth ₹9.29 crore for 65 X-ray units from Tamil Nadu. The firm is expanding internationally with TB initiatives in Indonesia and MRI installations in the Philippines, plus plans for 20 rehabilitation centers in Malaysia. In Aug'26, promoters infused approximately ₹59.67 crore via warrants and preferential allotment, increasing their stake from 62.15% to 63.08%. Collaborations include Vecura for AI-driven molecular research.
BRSR report for the FY 2025-26
Others (Uncategorized) · 08 Sept 2026, 2:40 am
Fischer Medical Ventures Releases FY25-26 Business Responsibility and Sustainability Report Fischer Medical Ventures submitted its standalone BRSR for FY25-26 on 7th Sep'26. Turnover stood at ₹1,739.18 Lakhs, with 100% generated from medical devices and software, and net worth reached ₹33,813.23 Lakhs. Total energy consumption was 193.76 GJ (intensity of 1.11 GJ/₹ Cr), and water consumption stood at 48.94 kl. Sourcing from domestic suppliers hit 91.46%, with 35.62% from MSMEs. The company reported zero worker injuries, zero product recalls, zero data breaches, and zero monetary regulatory penalties during the year.
33rd Annual Report of Fischer Medical Ventures Limited
Others (Uncategorized) · 08 Sept 2026, 2:12 am
33rd AGM of Fischer Medical Ventures Limited is scheduled to be held on 29.09.2026 at 11:00 AM IST
Annual General Meeting · 08 Sept 2026, 2:04 am
Fischer Medical Ventures Limited has informed the exchange on the presentation for the Investor/Analyst call scheduled to be held on 07.09.2026.
Intimation · 07 Sept 2026, 4:50 pm
Fischer Medical Ventures Outlines AI-Enabled Healthcare Platform Strategy Fischer Medical Ventures Ltd released an investor presentation detailing its vertically integrated healthcare platform spanning AI-enabled imaging, population screening, and hospital digitization. Operating via subsidiaries Time Medical and FlynnCare, its portfolio covers MRI (0.35T to 7.0T), CT, portable X-ray, and mammography systems alongside the MIDAS AI screening ecosystem and ATLAS analytics platform. The group also holds strategic stakes across portfolio assets, including Nanyang Biologics (51%), WonderTech (51%), SASCAN (19.9%), and NanoMedic (15%), targeting oncology, neurology, and preventative clinical applications globally across India, SEA, and MENA.
Fischer Medical Ventures Limited has informed the exchange on the Analyst/Investor Meet scheduled on 07-09-2026.
Intimation · 05 Sept 2026, 2:49 am
Fischer Medical Ventures Schedules Institutional Investor Meeting Fischer Medical Ventures Limited has scheduled a virtual, one-on-one meeting with institutional investors on 7th Sep'26 at 12:30 PM IST. Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, the discussion will focus on general business performance and publicly available information. The company noted that this intimation is submitted voluntarily given the one-on-one format of the engagement.
Fischer Medical Ventures Limited has informed the Exchange regarding Outcome of Board Meeting held on September 03, 2026.
Outcome · 03 Sept 2026, 8:16 pm
Fischer Medical Ventures Limited has informed the Exchange about outcome of Board meeting held on 03/09/2026
Outcome · 03 Sept 2026, 8:14 pm
Fischer Medical Ventures Appoints David Yeow as Independent Director and Reconstitutes Audit Committee Fischer Medical Ventures appointed Mr. David Yeow as an Additional Independent Director for a five-year term, effective 3rd Sep'26. Yeow, Principal at medical device VC Hunniwell Lake Ventures, brings over 30 years of technology commercialization expertise. Consequently, the Board reconstituted its Audit Committee, adding Yeow as a member alongside six others. Additionally, the company scheduled its 33rd AGM for 29th Sep'26 via video conferencing. To facilitate the AGM, the company's share transfer books will remain closed from 23rd Sep'26 to 29th Sep'26.
Intimation of Record Date for E-Voting and payment of Dividend to Shareholders
Dividend · 03 Sept 2026, 8:12 pm
Fischer Medical Ventures Sets Record Date for Dividend and 33rd AGM Fischer Medical Ventures Ltd announced its 33rd Annual General Meeting (AGM) is scheduled for 29th Sep'26. The company set 22nd Sep'26 as the record date for determining shareholder eligibility for dividend payments and e-voting rights. Additionally, the Register of Members and Share Transfer Books will remain closed from 23rd Sep'26 to 29th Sep'26. The cut-off date to determine eligibility for receiving the AGM notice dispatch is 4th Sep'26.
I)Approval of Appointment of Independed Director II)Approval of AGM Notice & Book Closure III) Reconstitution of Committee
Others (Uncategorized) · 03 Sept 2026, 8:07 pm
Fischer Medical Ventures Ltd informed the exchange on the Press Release titled Time Medical International Ventures launches Next-generation CLARION 64/128- Slice AI-driven CT system at ....
Press Release · 28 Aug 2026, 10:44 pm
Fischer Medical Launches Next-Gen AI-Driven CT System in India Fischer Medical Ventures (NSE: FISCHER) announced on 28 Aug'26 that its wholly-owned subsidiary, TMIV Imaging, has launched the CLARION 64/128-Slice AI-Driven CT System in India. Unveiled at the India Health Expo 2026, the new system aims to enhance diagnostic precision, operational efficiency, and patient throughput. The CLARION platform features advanced hardware and AI workflows, including a Liquid Metal Bearing X-ray tube and scalable configurations up to 128 slices, targeting applications from routine diagnostics to advanced cardiac, surgical, and interventional procedures.
Fischer Medical Ventures Limited has informed the exchange on the press release titled "Catanduanes Integrated Digital Healthcare project Awarded to Time Medical Philippines".
Press Release · 24 Aug 2026, 8:24 pm
Fischer Medical's Subsidiary Wins Digital Healthcare Project in the Philippines Fischer Medical Ventures' step-down subsidiary, Time Medical Philippines (TM-P), has won a province-wide digital healthcare project in Catanduanes, Philippines. Announced on 24 Aug'26, the project involves deploying an integrated solution combining Health Kiosks with the PhilHealth-accredited FlynnCare Clinic Management System (CMS). This marks the first province-wide implementation of this model, aiming to create a scalable blueprint for healthcare digitalization under the country's Universal Health Care program. The partnership seeks to establish sustainable recurring revenue models through scalable deployments in the Philippines and other markets.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shankar Varadharajan & Others
Acquisition/ Disposal of Shares · 18 Aug 2026, 10:24 pm
Fischer Medical Ventures: Promoter Group Acquires Shares via Warrant Conversion On 17th Aug'26, promoter group entities acquired 454,210 shares in Fischer Medical Ventures Ltd via a preferential allotment upon warrant conversion. Acquirer FMV Holdings Pte Ltd's stake increased from 50.74% to 50.78%, while PAC Mr. Shankar Varadharajan's holding remained at 12.31%. Consequently, the total promoter group holding (Acquirer + PACs) is now 63.08% of the company's total and diluted share capital. The acquisition was reported on 18th Aug'26 under SEBI's takeover regulations.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shankar Varadharajan & PACs
Acquisition/ Disposal of Shares · 18 Aug 2026, 4:25 pm
Fischer Medical Ventures Promoters Increase Stake via Warrant Conversion Promoters of Fischer Medical Ventures Ltd, Mr. Shankar Varadharajan and FMV Holdings Pte Ltd, increased their aggregate holding following a preferential allotment from warrant conversion on 14th Aug'26. Their combined stake rose from 63.00% to 63.06%. The acquisition involved 1.33 crore shares, representing 1.91% of the total capital. Post-transaction, the promoters' total holding stands at 44.07 crore shares, equivalent to a 63.08% diluted stake. The company's equity capital increased to Rs. 69.82 crore post-allotment.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shankar Varadharajan & Others
Acquisition/ Disposal of Shares · 18 Aug 2026, 4:24 pm
Fischer Medical Ventures: Promoter Group Increases Stake via Warrant Conversion On 13-Aug'26, promoters of Fischer Medical Ventures increased their aggregate stake to 63.00% from 62.66% via preferential allotment upon warrant conversion. The acquirers, Mr. Shankar Varadharajan and FMV Holdings Pte Ltd, acquired 15,00,000 and 97,78,217 shares, representing 0.22% and 1.44% of total share capital, respectively. Post-acquisition, the total promoter group holding stands at 44.07 crore shares. The total diluted share capital post-acquisition is Rs. 69.87 crore.
Allotment of equity shares pursuant to conversion of warrants
Others (Uncategorized) · 17 Aug 2026, 11:26 pm
Fischer Medical Allots Shares to Promoter via Warrant Conversion On 17th Aug'26, Fischer Medical Ventures' board approved the allotment of 4,54,210 equity shares to promoter entity FMV Holdings Pte Ltd. The allotment follows the conversion of warrants at a full issue price of Rs. 23.40 per share. The company received the final 75% of the exercise price, amounting to Rs. 79.71 lakhs, upon conversion. This action results in equity dilution and increases the promoter's holding, signaling confidence in the company's prospects.